Quarter End Results

Period Ended March 31, 2021

Forward looking statement

This presentation contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the

outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Further, certain forward looking statements are based upon assumptions of future events which may not prove to be accurate. The forward looking statements in this document speak only as at the date of this presentation. Genmab does not undertake any obligation to update or revise forward looking statements in this presentation nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

© Genmab

2

For Investor audience only. Not for public information or use. Not for promotional use.

Strategic

Partnerships,

Collaborations and

Licensing

Agreements

As part of the Genmab First Quarter End Results presentation, we will discuss several products developed in collaboration with strategic partners or that are the result of product or technology licenses with other companies. This slide is an acknowledgement of those relationships.

  • Partners for Genmab owned products ≥50%:
  • Seagen Inc.: tisotumab vedotin
  • AbbVie Inc.: epcoritamab, DuoHexaBody-CD37 (GEN3009), DuoBody-CD3x5T4 (GEN1044)
  • BioNTech SE: DuoBody-PD-L1x4-1BB (GEN1046), DuoBody-CD40x4-1BB (GEN1042)
  • Janssen Biotech, Inc.1: HexaBody-CD38 (GEN3014)
  • Companies developing products created by Genmab or that incorporate Genmab's innovation:
  • Janssen Biotech, Inc.: daratumumab, amivantamab
  • Novartis: ofatumumab
  • Horizon Therapeutics2: teprotumumab

1. Genmab is developing HexaBody-CD38 in an exclusive worldwide license and option agreement with Janssen Biotech, Inc; 2. Teprotumumab was created by Genmab under a collaboration with Roche and development and commercialization of the product is now being conducted by Horizon under a license from Roche.

© Genmab

3

3

For Investor audience only. Not for public information or use. Not for promotional use.

On the Road to 2025:

Evolving Into a Fully

Integrated Biotech

Core Purpose

To improve the lives of patients

by creating & developing innovative antibody products

Our Strategy

  • Focus on core competence
  • Turn science into medicine
  • Build a profitable & successful biotech

Vision

By 2025, our own product has transformed cancer treatment and we have a pipeline of knock-your-socks off antibodies

© Genmab

4

For Investor audience only. Not for public information or use. Not for promotional use.

Recent Key Achievements

Company & Pipeline

Highlights

  • Tisotumab vedotin
    • BLA submitted to U.S. FDA for patients with recurrent or metastatic cervical cancer
      • Accepted for priority review with target action date of October 10, 2021
      • Based on results of the innovaTV 204 pivotal Phase 2 study, published in The Lancet Oncology, April 2021
    • Potential JNDA filing timeline postponed to include Phase 3 innovaTV 301 data
    • First patient dosed in Phase 3 innovaTV 301 study of tisotumab vedotin versus chemotherapy in recurrent or metastatic cervical cancer
  • Epcoritamab
    • First patient dosed in Phase 3 study, triggering achievement of USD 40 million milestone in collaboration with AbbVie
  • HexaBody-CD38(GEN3014)
    • First patient dosed in first-in-human study in hematological malignancies
  • Tahi Ahmadi appointed Chief Medical Officer, Head of Experimental Medicines, member of Executive Management

© Genmab 5

For Investor audience only. Not for public information or use. Not for promotional use.

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original document
  • Permalink

Disclaimer

Genmab A/S published this content on 05 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 May 2021 15:16:00 UTC.